Bulk Ingredient
Qualifications and Restriction on Wholesaling
The bulk requirements in current section 503A are
preserved, with one modification.
Current law requires that any drug compounded from bulk must use bulk
active pharmaceutical ingredient that 1) either complies with an applicable
United States Pharmacopoeia (USP) or National Formulary (NF) monograph, is part
of an FDA-approved drug, or appears on a list established by the Secretary; 2) is
manufactured in a registered establishment; and 3) is accompanied by a valid
certificate of analysis. The revised section
503A would permit the Secretary to identify a drug that only has an applicable
USP or NF monograph as not suitable for compounding following the publication
of the reasoning and consideration of comments submitted to a docket open for
at least 30 days. Inactive ingredients also must comply with USP or NF.
If a drug is being compounded for a minor animal
species, the same requirements on bulk chemicals apply. However, if a drug is
compounded for a non-food major species or food-producing animal, compounding
from bulk can only be performed if FDA has listed that bulk ingredient. The
major species are cattle, horses, swine, chickens, turkeys, dogs, and cats.
Minor animal species are all other species.
Compounded drugs may only be sold by the entity that
compounded that product, and all must be labeled “not for resale”. It is a
prohibited act to resell a product labeled “not for resale”.
quoted from the Senate's section by section paper.
Do vets have a problem with this proposed new federal legislation? If so, you need to get your comments submitted by the May 3, 2013 deadline.
No comments:
Post a Comment